Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Blood

Volumn 123, Issue 25, 2014, Pages 3855-3863

  Bachanova, Veronika ^a   Cooley, Sarah ^a   Defor, Todd E ^a   Verneris, Michael R ^a   Zhang, Bin ^a   McKenna, David H ^b   Curtsinger, Julie ^b   Panoskaltsis Mortari, Angela ^a   Lewis, Dixie ^a   Hippen, Keli ^a   McGlave, Philip ^a   Weisdorf, Daniel J ^a   Blazar, Bruce R ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; INTERLEUKIN 15; INTERLEUKIN 7;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANDIDEMIA; CELL EXPANSION; CHILD; CHILL; CLINICAL OBSERVATION; CYTOMEGALOVIRUS INFECTION; DEPLETION; DISEASE FREE SURVIVAL; DONOR; DRUG EFFICACY; DYSPNEA; EFFECTOR CELL; FEMALE; FEVER; HAPLOIDY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; LEUKEMIA REMISSION; LUNG HEMORRHAGE; LUNG MYCOSIS; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NATURAL KILLER CELL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TYPHLITIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84902682889     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-532531     Document Type: Article

References (34)

1. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274. (Pubitemid 40563170)
2. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
3. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
4. Bachanova V, Burns LJ, McKenna DH, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59(11):1739-1744.
5. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107.
6. Gasteiger G, Kastenmuller W. Foxp3+ regulatory T-cells and IL-2: the Moirai of T-cell fates? Frontiers Immunol. 2012;3:179. doi:10:3389/fimmu.2012. 00179. eCollection 2012.
7. Foss FM. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000;1(Suppl 1):S27-S31.
8. Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114(18):3793-3802.
9. Hallett WH, Ames E, Alvarez M, et al. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant. 2008;14(10):1088-1099.
10. Yamada Y, Aoyama A, Tocco G, et al. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol. 2012;188(12):6063-6070.
11. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
12. McKenna DH, Kadidlo DM, Miller JS, Orchard PJ, Wagner JE, McCullough J. The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory. Transfus Med Rev. 2005;19(3):217-228. (Pubitemid 40943573)
13. Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80(9):2221-2229.
14. Hippen KL, Harker-Murray P, Porter SB, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 2008;112(7):2847-2857.
15. Kaplan EL. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16(8):901-910. (Pubitemid 27198953)
17. + Treg. J Immunol. 2012;189(12):5985-5994.
18. Cooley S, Foley B, Verneris MR, et al. Haploidentical natural killer (NK) cells expanding in vivo after adoptive transfer exhibit hyperfunction that partially overcomes self tolerance and leads to clearance of refractory leukemia. Blood. 2011;118(21):355[abstract].
19. Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002;13(6):429-439. (Pubitemid 35303814)
20. Gasteiger G, Hemmers S, Firth MA, et al. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med. 2013;210(6):1167-1178.
21. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med. 2013;210(6):1153-1165.
22. Chung DJ, Rossi M, Romano E, et al. Indoleamine 2,3-dioxygenase- expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 2009;114(3):555-563.
23. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol. 2012;189(11):5147-5154.
24. Li W, Green WR. Immunotherapy of murine retrovirus-induced acquired immunodeficiency by CD4 T regulatory cell depletion and PD-1 blockade. J Virol. 2011;85(24):13342-13353.
25. Charbonnier LM, Vokaer B, Lemaitre PH, Field KA, Leo O, Le Moine A. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transplantation. 2012;12(9):2313-2321.
26. Ghiringhelli F, Ménard C, Terme M, et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075-1085. (Pubitemid 41464501)
27. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43. doi:10.1126/scitranslmed.3005265.
28. Saito W, Kitamura H, Hijikata A, et al. Identification of therapeutic targets on quiscent chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9. doi:10.1126/scitranslmed.3000349.
29. Gerber JM, Gucwa JL, Esopi D, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4(5):715-728.
30. Cerny J, Yu H, Ramanathan M, et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013;160(2):262-266.
31. Tolar J, Curtsinger J, McElmurry R, et al. Optimal xenogeneic adoptive transfer of human NK cells: Fresh NK cells and IL-15 administration are superior to frozen NK cells and IL-2. Blood. 2012;120(21).
32. Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE. 2012;7(1):e30264.
33. Lapteva N, Durett AG, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14(9):1131-1143.
34. Cooley S, Verneris MR, Curtsinger J, et al. Recombinant human IL-15 promotes in vivo expansion of adoptively transferred NK cells in a first-in-human phase I dose escalation study in patients with AML. Blood. 2012;120:894[abstract].